BANK VONTOBEL/PUT/ROCHE GS/180/0.1/21.03.25 Stock

Warrant

DE000VD3VR06

Real-time Boerse Frankfurt Warrants 04:12:44 2024-07-01 EDT
0.147 EUR -2.00% Intraday chart for BANK VONTOBEL/PUT/ROCHE GS/180/0.1/21.03.25
1 month-44.44%
Date Price Change
24-07-01 0.147 -2.00%
24-06-28 0.15 -3.23%
24-06-27 0.155 -4.32%
24-06-26 0.162 +5.19%
24-06-25 0.154 +3.36%

Real-time Boerse Frankfurt Warrants

Last update July 01, 2024 at 04:12 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellPUT
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VD3VR0
ISINDE000VD3VR06
Date issued 2024-04-10
Strike 180 CHF
Maturity 2025-03-21 (264 Days)
Parity 10 : 1
Emission price 0.33
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 0.43
Lowest since issue 0.147
Spread 0.01
Spread %6.29%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
249.5 CHF
Average target price
278.1 CHF
Spread / Average Target
+11.44%
Consensus